Men's Health News

RSS

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Researchers discover new explanation for differences in severity of mental illness in males

Researchers have discovered a new explanation for differences in the severity of mental illness in males. The more excess copies of a certain gene, the more serious the handicap. The genetic defect is situated on the X-chromosome; and it is suspected that it is the amount of copies of the GDI1 gene that is responsible.

11 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

The West African Rotavirus Advisory Board is calling on governments to vaccinate children against rotavirus, IRIN reports. At a recent meeting in Dakar, Senegal, which was "financed by GlaxoSmithKline, makers of one of two rotavirus vaccines" the board issued a document recommending that governments "immediately recognize the magnitude of the rotavirus problem and make vaccination against the virus a priority" (12/8).

8 Dec 2009

Exercise can reduce overall mortality rates in patients with prostate cancer, according to findings

As little as 15 minutes of exercise a day can reduce overall mortality rates in patients with prostate cancer, according to findings presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held here, Dec. 6-9, 2009.

8 Dec 2009

Data shows strong inverse association between coffee consumption and advanced prostate cancer

While it is too early for physicians to start advising their male patients to take up the habit of regular coffee drinking, data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference revealed a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Regular sexual activity can help improve the overall health in men

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released the top ten reasons regular sexual activity can help improve men’s overall health. From decreased blood pressure to more restful sleep, sexual activity is essential for maintaining bodily functions as well as overall health and well-being.

7 Dec 2009

Gamma Labs sponsors the Charles Evans PCF Pro/Am Tour

On December 1, 2009 at the annual Prostate Cancer Foundation Annual Dinner, the organization acknowledged its sponsors and provided insight of the year’s events and milestones. Gamma Labs, a leading nutritional supplement company, was recognized as one of the organization’s sponsors. Gamma Labs is pleased to announce today plans to continue support of this organization. Gamma Labs serves as a sponsor for the Charles Evans PCF Pro/Am Tour, an annual event that benefits the Prostate Cancer Foundation.

5 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

Weight loss - an effective treatment for sleep apnoea in obese men

For obese men, a dramatic weight loss can be an effective way to improve moderate to severe sleep apnoea, scientists at the Swedish medical university Karolinska Institutet report. Those with severe sleep apnoea when the study began benefited most from weight loss.

4 Dec 2009

Low energy diet improves obstructive sleep apnoea in obese men

Weight loss reduces obstructive sleep apnoea in obese men, with the greatest effect seen in patients with severe disease, according to new research published on bmj.com today.

4 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

Continued rise of PSA value in prostate cancer patients can indicate relapsing disease

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

3 Dec 2009

Sperm from men with NOA and OA capable of producing embryos

It has been thought that men with non-obstructive azoospermia (NOA), a lack of sperm in the semen not caused by an obstruction within the reproductive system, are poor candidates for IVF. Now, researchers writing in the open access journal Reproductive Biology and Endocrinology have shown that sperm from men with NOA and obstructive azoospermia (OA) are equally capable of producing embryos.

3 Dec 2009

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five.

2 Dec 2009

Majority of Canadians join global charity event to raise awareness on prostate cancer

Movember, the month formerly known as November, is proud to share that 35,068 Canadians across the country joined the movement by growing a Mo (slang for moustache) and supporting men's health issues. This year over $6.3 million has been raised for Prostate Cancer Canada, with funds continuing to pour in.

1 Dec 2009

Control over male fertility and hope for low sperm count

A new research report published in the December 2009 print issue of The FASEB Journal could one day give men similar type of control over their fertility that women have had since the 1960s. That's because scientists have found how and where androgenic hormones work in the testis to control normal sperm production and male fertility. This opens a promising avenue for the development of "the pill" for men. The discovery also offers hope to those who cannot have children because of low sperm counts.

1 Dec 2009

Sentinelle Medical, Siemens Healthcare to jointly develop solutions for Interventional Prostate MRI

Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and software, and Siemens Healthcare today announced at the Radiological Society of North America (RSNA) annual meeting in Chicago, that they are collaborating on the development of a suite of innovative solutions for Interventional Prostate MRI.

30 Nov 2009

Healthy dietary habits are important for GCA prevention

The gastric cardiac adenocarcinoma (GCA) is a very rare disease. In recent decades, however, the incidence of the GCA has increased dramatically in many Western countries. An increasing trend in GCA is also observed in municipal regions but not in rural regions of China. Another striking feature is the strong male predominance among patients with GCA. Some of the reasons above are still unclear and require further epidemiological investigations.

26 Nov 2009

Men's Health News

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Researchers discover new explanation for differences in severity of mental illness in males

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

Exercise can reduce overall mortality rates in patients with prostate cancer, according to findings

Data shows strong inverse association between coffee consumption and advanced prostate cancer

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Regular sexual activity can help improve the overall health in men

Gamma Labs sponsors the Charles Evans PCF Pro/Am Tour

Results from Phase III pivotal study of FIRMAGON presented

Weight loss - an effective treatment for sleep apnoea in obese men

Low energy diet improves obstructive sleep apnoea in obese men

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Continued rise of PSA value in prostate cancer patients can indicate relapsing disease

Sperm from men with NOA and OA capable of producing embryos

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Majority of Canadians join global charity event to raise awareness on prostate cancer

Control over male fertility and hope for low sperm count

Sentinelle Medical, Siemens Healthcare to jointly develop solutions for Interventional Prostate MRI

Healthy dietary habits are important for GCA prevention

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News